Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
Gastrointest Endosc. 2024 Jun;99(6):867-885.e64. doi: 10.1016/j.gie.2023.12.004. Epub 2024 Apr 19.
This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ≥ 30 kg/m, or with a BMI of 27.0-29.9 kg/m with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.
本 ASGE-ESGE 联合指南提供了关于内镜减重和代谢治疗(EBMT)在肥胖管理中作用的循证总结和建议。该文件采用了推荐分级的评估、制定与评价(GRADE)框架制定。它评估了目前具有 CE 标志或 FDA 许可/批准的 EBMT 设备和程序,或在文件制定后五年内获得批准的设备和程序的疗效和安全性。该指南建议在 BMI≥30kg/m2的患者中使用 EBMT 联合生活方式改变,或在 BMI 为 27.0-29.9kg/m2且至少存在 1 种肥胖相关合并症的患者中使用。此外,它建议在该患者人群中,将胃内球囊和内镜胃重建(EGR)设备与生活方式改变联合使用。